IDEAYA Biosciences, Inc. $IDYA Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC decreased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 15.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 93,152 shares of the company’s stock after selling 16,655 shares during the period. Rafferty Asset Management LLC’s holdings in IDEAYA Biosciences were worth $2,535,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. General American Investors Co. Inc. increased its holdings in shares of IDEAYA Biosciences by 7.7% during the 3rd quarter. General American Investors Co. Inc. now owns 280,261 shares of the company’s stock worth $7,626,000 after buying an additional 20,000 shares during the last quarter. Candriam S.C.A. grew its position in IDEAYA Biosciences by 10.8% during the third quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock valued at $27,563,000 after acquiring an additional 98,567 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new stake in IDEAYA Biosciences during the third quarter valued at about $934,000. Envestnet Asset Management Inc. increased its stake in IDEAYA Biosciences by 174.0% during the third quarter. Envestnet Asset Management Inc. now owns 299,032 shares of the company’s stock worth $8,137,000 after acquiring an additional 189,877 shares during the last quarter. Finally, Creative Planning raised its holdings in shares of IDEAYA Biosciences by 99.4% in the 2nd quarter. Creative Planning now owns 121,684 shares of the company’s stock worth $2,558,000 after purchasing an additional 60,667 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Wall Street Zen lowered shares of IDEAYA Biosciences from a “buy” rating to a “sell” rating in a research report on Saturday, February 21st. Royal Bank Of Canada restated an “outperform” rating and set a $49.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. UBS Group assumed coverage on IDEAYA Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday, January 22nd. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, IDEAYA Biosciences has an average rating of “Moderate Buy” and a consensus price target of $48.69.

Insider Buying and Selling at IDEAYA Biosciences

In related news, Director Jeffrey Stein purchased 50,000 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were purchased at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the acquisition, the director directly owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. The trade was a 1,167.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.50% of the company’s stock.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $34.68 on Thursday. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $39.28. The firm has a 50-day moving average of $33.95 and a two-hundred day moving average of $31.07. The stock has a market cap of $3.05 billion, a P/E ratio of -26.47 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.09. The business had revenue of $21.75 million for the quarter, compared to analyst estimates of $5.95 million. During the same quarter last year, the business earned ($1.49) EPS. IDEAYA Biosciences’s revenue for the quarter was up 55.7% compared to the same quarter last year. As a group, equities analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.